Navigation Links
Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
Date:12/13/2007

Summary: Genmab has Announced Details of a Planned Phase II Study of

Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis

COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab's collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 receptor. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"Multiple sclerosis is a debilitating disease for which there are currently few treatments," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We hope our fully human antibody, ofatumumab, may offer another potential treatment option for patients suffering from this incapacitating disease."

About the trial

The double blind randomized trial will consist of two parts. Part A will include approximately 36 patients in one of three increasing dose cohorts (100 mg, 300 mg or 700 mg of ofatumumab) randomized to receive ofatumumab or placebo. An independent data monitoring committee (IDMC) will evaluate the safety of each sequential cohort prior to progression to the next cohort. When all patients in Part A have had their week 4 MRI scan, the IDMC will evaluate the data before Part B of the study begins.

Part B will consist of a 48 week treatment period of approximately 288 patients. Patients will be randomized to treatment with 100 mg, 300 mg, or 700 mg of ofatu
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... its potential to revolutionize the world has attracted ... corporations and small start-ups. The early years of ... projects largely due to the high risks involved, ... budgets earmarked for this evolving technology have been ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... isn't enough. Researchers at the University of Wisconsin-Madison, among ... tightly networked computers that share tasks such as analyzing ... David Schwartz are working with the Grid Laboratory ... The system used is Condor, software developed in-house to ...
... this past Sunday? , ,Yes, it was Mother's Day, and ... in Europe"), but it was also the 106th anniversary of ... world's greatest economists. These days, while Hayek is mostly remembered ... "The Road to Serfdom," he was also a former professor ...
...
Cached Biology Technology:Midwest cities in fight over municipal broadband access 2Midwest cities in fight over municipal broadband access 3Midwest cities in fight over municipal broadband access 4
(Date:9/19/2014)... will study multifunctional and specialized spinal cord nerve ... Science Foundation grant in the amount of $680,000 ... in the Department of Biology, OU College of ... between the multifunctional and specialized spinal cord nerve ... what connections they make. Berkowitz will collaborate ...
(Date:9/19/2014)... Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ("Nxt-ID" or ... market, updates the "Wocket in Your Pocket" celebrity ad campaign, featuring ... weight classes, Vinny Pazienza (PAZ). , ... Thrones actor Ciaran Hinds and Sons of ... Sagal have been cast in Bleed for This . ...
(Date:9/18/2014)... Bulletin study uses tree rings to document arroyo ... in northern New Mexico, USA. By determining burial dates ... were able to precisely date arroyo sedimentary beds 30 ... with aerial imagery, LiDAR, longitudinal profiles, and repeat surveys ... are deep, oversized channels that have vertical or steeply ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... 12 Orchid Cellmark Inc.,(Nasdaq: ORCH ) today ... of Orchid, is scheduled to present at the 2008 ... Wednesday, May 14, 2008 at,3:20 p.m. PDT., Mr. ... the,company,s recent and ongoing progress. A link to the ...
... most attractive male birds attract more females and as a ... the starting point of many studies looking for factors that ... assume that birds see what we see? In a study ... show that our human vision is not an adequate instrument. ...
... taken two unlikely distant cousins turkeys and scallops - ... University of Leeds researchers have found that a motor protein, ... , The discovery suggests that the tiny motor protein ... humans it may even hold a key to understanding potentially ...
Cached Biology News:Human vision inadequate for research on bird vision 2Ancient protein offers clues to killer condition 2
...
... Kits synthesize RNA probes with specific activities ... High specific activity, single-stranded RNA probes are ... hybridization, and blot hybridizations. MAXIscript Kits can ... modest amounts of unlabeled RNA (2-4 g/20ul ...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
... liquid controls for monitoring Aldolase tests. ... abnormal) with targeted manufacturing values at ... ± 3 IU/L. 30-day shelf ... 2-8 C. Level 1: 3 x ...
Biology Products: